Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
US10286070B2 · kind B2 · utility
2Cited by
10References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 11, 2017 |
| Grant date | May 14, 2019 |
| Priority date | — |
| Expiry date | Jan 11, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating cancer or metastasis is provided involving administering at least one oncostatin M (OSM) antagonist to a subject, wherein the subject has been diagnosed with cancer. Administration of an OSM antagonist such as a small molecule pharmaceutical is provided as well as an anti-OSM antibody, an anti-OSM aptamer, and an OSM mRNA antagonist. The OSM antagonists were found to inhibit or prevent tumor cell detachment, proliferation and metastasis in several cancer types.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.